BRAIN-2 COVID-19 Administrative Supplement

BRAIN-2 COVID-19 行政补充

• 批准号: 10204693
• 负责人: E Wesley ELY
• 金额: $ 86.82万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-15 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10204693
• 关键词: 2019-nCoV; Acute; Administrative Supplement; Affect; Aging; Agitation; Alzheimer' s Disease; Alzheimer' s disease related dementia; Autopsy; Blood Coagulation Disorders; Brain; Brain Stem; Brain region; COVID-19; COVID-19 pandemic; Case Study; Cerebral hemisphere; Collaborations; Communities; Conscious; Critical Illness; Delirium; Dementia; Development; Encephalitis; Functional disorder; Funding; Future; Grant; Guillain-Barré Syndrome; Headache; Impairment; Incidence; Infection; Inflammation; Intensive Care Units; Magnetic Resonance Imaging; Memory; National Institute on Aging; Nervous system structure; Neurodegenerative Disorders; Neuropathy; Neuropsychology; Parents; Patients; Publishing; Research; Resource Sharing; Resources; Risk Factors; Seizures; Series; Signs and Symptoms; Structural defect; Survivors; Symptoms; Viral; Vision; brain tissue; data hub; experience; in vivo; indexing; inflammatory marker; interest; neuropathology; ranpirnase; religious order study; repository; response; viral RNA

The NIA-funded BRAIN-ICU-2 Study [Bringing to light the Risk factors And Incidence of Neuropsychological dysfunction (dementia) in ICU Survivors, 2nd Study] will define the relationship between ICU delirium and dementia. The proposed administrative supplement to BRAIN-ICU-2 Study (R01 AG58639) is in response to NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-022; PA-18-591). To understand the brain tissue damage of acute delirium caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), we will perform new neuropathological studies of critically ill patients affected by COVID-19, as well as those with Alzheimer’s disease and related dementia (ADRD) with/without critical illness. By studying COVID-19, we will better understand the relationship between delirium and ADRD. During the current COVID-19 pandemic, intensive care units (ICU’s) across the nation are awash with patients experiencing delirium, a major ICU risk factor for future ADRD. These delirium symptoms of impaired consciousness include headache, alteration of gustatory, olfactory, and visual function, neuropathy, seizures, agitation, encephalitis, and/or Guillain-Barre syndrome. These delirium signs and symptoms could be due to SARS-CoV-2 infection of the brain, particularly in those with ADRD. We do not know if there are direct nervous system consequences of COVID-19 (e.g., inflammation), and/or indirect nervous system consequences, e.g., coagulopathy. To our knowledge, limited autopsy series that included brain tissue have been published. No information about ADRD was provided. The proposed supplement will specifically compare multiple groups of patients, ICU patients with/without ADRD with/without COVID-19, along with non-ICU patients with/without ADRD and with/without COVID-19. The BRAIN-ICU-2 study will provide ICU patients with/without ADRD with/without COVID-19. The NIA-supported Religious Orders Study (ROS; P30 AG10161, R01 AG15819), and Rush Memory and Aging Project (MAP; R01 AG17917) will provide non-ICU patients with/without ADRD and with/without COVID-19. The proposed supplement will further build on collaboration between the Vanderbilt and Rush BRAIN-ICU-2 study teams, and represent the most comprehensive neuropathologic examination of COVID-19 brains compared to non-COVID-19 brains, in those with/without ADRD, and with/without critical illness. This supplement will create a unique resource for the world-wide COVID-19 research community, with a strong and sustained impact on the fields of ICU delirium and ADRD.

NIA资助的Brain-ICU-2研究[揭示了神经心理学的危险因素和事件 ICU幸存者中的功能障碍（痴呆症），第二项研究将定义ICU del妄与 失智。拟议的Brain-ICU-2研究（R01 AG58639）的行政补充是针对 NIA的行政补品可用性和修订补品2019年冠状病毒疾病 （COVID-19）（NOT-AG-022; PA-18-591）。了解由 严重的急性呼吸综合征冠状病毒2（SARS-COV-2），我们将进行新的神经病理学 研究受到COVID-19的危重患者，以及患有阿尔茨海默氏病及其相关患者的研究 痴呆症（ADRD），患有/没有危重疾病。通过研究Covid-19，我们将更好地了解这种关系 在Delirum和Adrd之间。在当前的Covid-19大流行期间，重症监护病房（ICU） 民族对del妄的患者感到震惊，这是未来ADRD的主要ICU风险因素。这些ir妄 意识障碍的症状包括标题，味觉改变，嗅觉和视觉功能， 神经病，癫痫发作，躁动，脑炎和/或吉兰 - 巴里综合征。这些ir妄的标志和 症状可能是由于大脑的SARS-COV-2感染，尤其是在ADRD的大脑中。我们没有 知道COVID-19（例如炎症）和/或间接是否有直接神经系统的后果 神经系统的后果，例如凝血病。据我们所知，包括有限的尸检系列 脑组织已发表。没有提供有关ADRD的信息。拟议的补充剂将 特定比较了多组患者，具有/不具有ADRD的ICU患者，有/不带有COVID-19的患者， 具有/没有ADRD的非ICU患者以及/不具有COVID-19的患者。 Brain-ICU-2研究将提供ICU 患有/没有ADRD的患者，有/没有COVID-19。 NIA支持的宗教秩序研究（ROS； P30 AG10161，R01 AG15819）和Rush记忆和老化项目（MAP; R01 AG17917）将提供非ICU 患有/没有ADRD的患者，患有/不具有COVID-19的患者。拟议的补充剂将进一步建立 Vanderbilt和Rush Brain-ICU-2研究团队之间的合作，代表最大的 与非旋转19的大脑相比 有/没有ADRD，并且患有/没有危重疾病。该补充将为 世界范围内的COVID-19研究社区，对ICU deli妄领域产生了强烈而持续的影响 和Adrd。